Invention Grant
- Patent Title: Use of a VEGF antagonist to treat angiogenic eye disorders
-
Application No.: US17740744Application Date: 2022-05-10
-
Publication No.: US11559564B2Publication Date: 2023-01-24
- Inventor: George D. Yancopoulos
- Applicant: REGENERON PHARMACEUTICALS, INC.
- Applicant Address: US NY Tarrytown
- Assignee: REGENERON PHARMACEUTICALS, INC.
- Current Assignee: REGENERON PHARMACEUTICALS, INC.
- Current Assignee Address: US NY Tarrytown
- Agent Thomas Triolo; Karl Bozicevic
- Main IPC: A61K38/17
- IPC: A61K38/17 ; C07K14/71 ; C07K19/00 ; C07K16/22 ; A61K9/00 ; A61K39/00

Abstract:
The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
Public/Granted literature
- US20220273764A1 Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders Public/Granted day:2022-09-01
Information query
IPC分类: